Older age increased the risk of major hemorrhage in atrial fibrillation patients, with an average rate increase of 1.2 (95% CI 1.0-1.4) per older age category on warfarin.
Cohort (n=13,559)
Does older age increase the risk of major hemorrhage in patients with nonvalvular atrial fibrillation, whether or not they are taking warfarin?
Older age independently increases the risk of major hemorrhage in patients with atrial fibrillation regardless of warfarin use, though carefully monitored warfarin therapy remains reasonably safe in older patients.
Effect estimate: Rate increase 1.2 (warfarin) / 1.5 (off warfarin) (95% CI 1.0-1.4 (warfarin) / 1.3-1.8 (off warfarin))
OBJECTIVES: To assess whether older age is independently associated with hemorrhage risk in patients with atrial fibrillation, whether or not they are taking warfarin therapy. DESIGN: Cohort study. SETTING: Integrated healthcare delivery system. PARTICIPANTS: Thirteen thousand five hundred fifty‐nine adults with nonvalvular atrial fibrillation. MEASUREMENTS: Patient data were collected from automated clinical and administrative databases using previously validated search algorithms. Medical charts were reviewed from patients hospitalized were for major hemorrhage (intracranial, fatal, requiring ≥2 units of transfused blood, or involving a critical anatomic site). Age was categorized into four categories (<60, 60–69, 70–79, and ≥80), and multivariable Poisson regression was used to assess whether major hemorrhage rates increased with age, stratified by warfarin use and adjusted for other clinical risk factors for hemorrhage. RESULTS: A total of 170 major hemorrhages were identified during 15,300 person‐years of warfarin therapy and 162 major hemorrhages during 15,530 person‐years off warfarin therapy. Hemorrhage rates rose with older age, with an average increase in hemorrhage rate of 1.2 (95% confidence interval (CI) 1.0–1.4) per older age category in patients taking warfarin and 1.5 (95% CI=1.3–1.8) in those not taking warfarin. Intracranial hemorrhage rates were significantly higher in those aged 80 and older (adjusted rate ratio=1.8, 95% CI=1.1–3.1 for those taking warfarin, adjusted rate ratio=4.7, 95% CI=2.4–9.2 for those not taking warfarin) than in those younger than 80. CONCLUSION: Older age increases the risk of major hemorrhage, particularly intracranial hemorrhage, in patients with atrial fibrillation, whether or not they are taking warfarin. Hemorrhage rates were generally comparable with those reported in previous randomized trials, indicating that carefully monitored warfarin therapy can be used with reasonable safety in older patients.
Fang et al. (Fri,) conducted a cohort in Nonvalvular atrial fibrillation (n=13,559). Older age vs. Younger age was evaluated on Major hemorrhage (Rate increase 1.2 (warfarin) / 1.5 (off warfarin), 95% CI 1.0-1.4 (warfarin) / 1.3-1.8 (off warfarin)). Older age increased the risk of major hemorrhage in atrial fibrillation patients, with an average rate increase of 1.2 (95% CI 1.0-1.4) per older age category on warfarin.